136 related articles for article (PubMed ID: 38284515)
1. Safety and Pharmacokinetics of Quizartinib Combination Therapy With Standard Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Results from Two Phase 1 Trials in Japan and China.
Qi J; Choi I; Ota S; Ichikawa S; Fujishima N; Iida H; Sugiura I; Sugiura K; Murata Y; Inoue H; Ohwada S; Wang J
Clin Pharmacol Drug Dev; 2024 May; 13(5):560-571. PubMed ID: 38284515
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study.
Usuki K; Handa H; Choi I; Yamauchi T; Iida H; Hata T; Ohwada S; Okudaira N; Nakamura K; Sakajiri S
Int J Hematol; 2019 Dec; 110(6):654-664. PubMed ID: 31359361
[TBL] [Abstract][Full Text] [Related]
3. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.
Erba HP; Montesinos P; Kim HJ; Patkowska E; Vrhovac R; Žák P; Wang PN; Mitov T; Hanyok J; Kamel YM; Rohrbach JEC; Liu L; Benzohra A; Lesegretain A; Cortes J; Perl AE; Sekeres MA; Dombret H; Amadori S; Wang J; Levis MJ; Schlenk RF;
Lancet; 2023 May; 401(10388):1571-1583. PubMed ID: 37116523
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.
Altman JK; Foran JM; Pratz KW; Trone D; Cortes JE; Tallman MS
Am J Hematol; 2018 Feb; 93(2):213-221. PubMed ID: 29139135
[TBL] [Abstract][Full Text] [Related]
5. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
6. Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.
Cortes JE; Khaled S; Martinelli G; Perl AE; Ganguly S; Russell N; Krämer A; Dombret H; Hogge D; Jonas BA; Leung AY; Mehta P; Montesinos P; Radsak M; Sica S; Arunachalam M; Holmes M; Kobayashi K; Namuyinga R; Ge N; Yver A; Zhang Y; Levis MJ
Lancet Oncol; 2019 Jul; 20(7):984-997. PubMed ID: 31175001
[TBL] [Abstract][Full Text] [Related]
7. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of quizartinib in Japanese patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia in an open-label, phase 2 study.
Takahashi T; Usuki K; Matsue K; Ohno H; Sakura T; Imanaka R; Murakami M; Ohwada S; Takagi T; Sakajiri S
Int J Hematol; 2019 Dec; 110(6):665-674. PubMed ID: 31473943
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.
Cortes JE; Kantarjian H; Foran JM; Ghirdaladze D; Zodelava M; Borthakur G; Gammon G; Trone D; Armstrong RC; James J; Levis M
J Clin Oncol; 2013 Oct; 31(29):3681-7. PubMed ID: 24002496
[TBL] [Abstract][Full Text] [Related]
10. Phase 2b study of 2 dosing regimens of quizartinib monotherapy in
Cortes JE; Tallman MS; Schiller GJ; Trone D; Gammon G; Goldberg SL; Perl AE; Marie JP; Martinelli G; Kantarjian HM; Levis MJ
Blood; 2018 Aug; 132(6):598-607. PubMed ID: 29875101
[TBL] [Abstract][Full Text] [Related]
11. Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.
Wang F; Huang J; Guo T; Zheng Y; Zhang L; Zhang D; Wang F; Naren D; Cui Y; Liu X; Qu Y; Luo H; Yang Y; Wei H; Guo Y
Biochem Pharmacol; 2021 Jun; 188():114538. PubMed ID: 33831397
[TBL] [Abstract][Full Text] [Related]
12. Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia.
Kang D; Ludwig E; Jaworowicz D; Huang H; Fiedler-Kelly J; Cortes J; Ganguly S; Khaled S; Krämer A; Levis M; Martinelli G; Perl A; Russell N; Abutarif M; Choi Y; Mendell J; Yin O
J Clin Pharmacol; 2020 Dec; 60(12):1629-1641. PubMed ID: 32598495
[TBL] [Abstract][Full Text] [Related]
13. Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Li J; Kankam M; Trone D; Gammon G
Br J Clin Pharmacol; 2019 Sep; 85(9):2108-2117. PubMed ID: 31173645
[TBL] [Abstract][Full Text] [Related]
14. A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics.
Li J; Trone D; Mendell J; O'Donnell P; Cook N
Cancer Chemother Pharmacol; 2019 Oct; 84(4):799-807. PubMed ID: 31385001
[TBL] [Abstract][Full Text] [Related]
15. A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Cooper TM; Cassar J; Eckroth E; Malvar J; Sposto R; Gaynon P; Chang BH; Gore L; August K; Pollard JA; DuBois SG; Silverman LB; Oesterheld J; Gammon G; Magoon D; Annesley C; Brown PA
Clin Cancer Res; 2016 Aug; 22(16):4014-22. PubMed ID: 26920889
[TBL] [Abstract][Full Text] [Related]
16. Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.
Martínez-Cuadrón D; Rodríguez-Macías G; Rodríguez-Veiga R; Boluda B; Montesinos P
Clin Drug Investig; 2020 Mar; 40(3):227-235. PubMed ID: 31912423
[TBL] [Abstract][Full Text] [Related]
17. Quizartinib for the treatment of acute myeloid leukemia.
Garcia-Horton A; Yee KW
Expert Opin Pharmacother; 2020 Dec; 21(17):2077-2090. PubMed ID: 32772726
[TBL] [Abstract][Full Text] [Related]
18. Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant.
Sandmaier BM; Khaled S; Oran B; Gammon G; Trone D; Frankfurt O
Am J Hematol; 2018 Feb; 93(2):222-231. PubMed ID: 29090473
[TBL] [Abstract][Full Text] [Related]
19. The FLT3 inhibitor quizartinib inhibits ABCG2 at pharmacologically relevant concentrations, with implications for both chemosensitization and adverse drug interactions.
Bhullar J; Natarajan K; Shukla S; Mathias TJ; Sadowska M; Ambudkar SV; Baer MR
PLoS One; 2013; 8(8):e71266. PubMed ID: 23967177
[TBL] [Abstract][Full Text] [Related]
20. Q-HAM: a multicenter upfront randomized phase II trial of quizartinib and high-dose Ara-C plus mitoxantrone in relapsed/refractory AML with FLT3-ITD.
Jaramillo S; Le Cornet L; Kratzmann M; Krisam J; Görner M; Hänel M; Röllig C; Wass M; Scholl S; Ringhoffer M; Reichart A; Steffen B; Kayser S; Mikesch JH; Schaefer-Eckart K; Schubert J; Geer T; Martin S; Kieser M; Sauer T; Kriegsmann K; Hundemer M; Serve H; Bornhäuser M; Müller-Tidow C; Schlenk RF
Trials; 2023 Sep; 24(1):591. PubMed ID: 37715270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
